C. R. M. PRENTICE From the University Department ofMedicine, Royal Infirmary, Glasgow Vascular disease accounts for more than 50 % of deaths and in most cases the cause lies in obstruction to blood flow by the twin perils of atheroma formation and thrombosis.
The major constituents of thrombi are platelets and fibrin, together with trapped red cells and other elements. Our main antithrombotic drugs are the antiplatelet agents to prevent platelets sticking together; anticoagulants to prevent fibrin formation; and fibrinolytic agents which, hopefully, will lyse and remove formed fibrin deposits. Antithrombotic therapy may also conveniently be classified as (1) prophylactic, to cover an event, such as a surgical operation, known to be associated with an increased thrombotic risk, and (2) therapeutic, to treat a thrombus which has already formed. It must also be remembered that the problems of arterial and venous thrombosis are different. Arterial thrombi are composed largely of aggregated platelets, together with fibrin; it is thought that platelet adhesion to the vessel wall is an important event which may initiate arterial thrombosis. Conversely, thrombi formed in veins consist mainly of fibrin and it is in this situation where the conventional anticoagulants are likely to be useful.
Antiplatelet Agents
First, I will give a brief account of the platelet aggregation process, and then continue with an account of the proposed mechanism by which some of the antiplatelet agents operate. Activation of the platelet membrane can be carried out by stimuli, such as ADP, collagen, basement membrane, thrombin, adrenaline, serotonin, and antigenantibody complexes. The common pathway of activation may be related to the level of cyclic-AMP within the platelet. Most of the aggregating agents tend to diminish cyclic-AMP production by inhibiting adenylcyclase, as seen in the figure. Conversely antiplatelet agents increase the level of platelet cyclic-AMP. This is achieved in two ways. First, increased production of cyclic-AMP by stimulation of adenylcyclase activity is caused by agents such as the prostaglandins. Second One advantage of the antiplatelet agents is that they appear to be free from haemorrhagic complications. This is in contrast to the anticoagulants and fibrinolytic agents, both of which are associated with significant haemorrhagic side effects.
The Anticoagulants
The anticoagulants inhibit the coagulation enzyme sequence which causes fibrin formation. Anticoagulants form three main groups: heparin, the coumadin compounds, and ancrod. Prentice, unpublished) .
The two main methods of giving heparin are either by six hourly intermittent injections or by continuous intravenous infusion. We prefer the latter method as a more uniform plasma concentration is obtained, although neither method has been the subject of sufficient clinical evaluation.
One problem about heparin in the treatment of arterial thrombosis is that it may enhance platelet aggregation. We have studied the effects of therapeutic concentrations of heparin in modifying ADPinduced platelet aggregation. Heparin enhanced the aggregating effect of ADP and lowered the threshold at which the release reaction and secondary platelet aggregation took place (Thomson, Forbes, and Prentice, 1973) . We have also found that platelet deposition and fibrin formation may take place on extracorporeal membranes during haemodialysis, despite the fact that the patient is heparinized sufficiently to prolong the whole blood clotting time 51 to over 60 minutes (Lindsay, Prentice, Ferguson, Burton, and McNicol, 1972 (Hemker, Veltkamp, and Loeliger, 1968) .
The chief complication of all anticoagulants is, of course, haemorrhage. The cause of the haemorrhage is usually due either to excessive dosage of the anticoagulants or to an unidentified source of haemorrhage, such as a peptic ulcer.
One major problem of the oral anticoagulants is that they interact with numerous other drugs with the result that their effect may either b_ diminished or increased (Eipe, 1972 (O'Reilly, 1970) . Individuals may take up to twenty times the normal dose yet show merely the normal or even less than normal anticoagulant effect. The absorption rate, albumin binding, and turnover rate in these families are normal. The defect appears to lie in an altered affinity of the hepatic receptor site for the anticoagulant and for vitamin K, caused by a single dominant effect on an autosomal chromosome.
ANCROD
Ancrod is the purified coagulant fraction of the venom of Agkistrodon rhodostoma, the Malayan pit viper. This enzyme removes fibrinopeptide A from fibrinogen leading to the formation of an unstable form of fibrin which is rapidly removed from the circulation by fibrinolysis (Ewart, Hatton, Basford, and Dodgson, 1970) . We have evidence to suggest that the fibrin is cleared from the circulation as soon as it is in the form of high molecular weight soluble fibrin complexes, and that the formation of insoluble 'micro-thrombi' does not occur under normal circumstances (McKillop, Edgar, Forbes, and Prentice, 1975) . One interesting consequence of defibrination by ancrod is that the whole blood and plasma viscosity are diminished. This may be an important effect in promoting blood flow in small vessels and there are encouraging reports from the Continent that ancrod may be helpful in the treatment of peripheral arterial diseases. (Prentice and McNicol, 1973) . Although streptokinase and urokinase can, in massive pulmonary embolism, lower the pulmonary artery pressure more rapidly than heparin. no beneficial effect on the mortality from 53 pulmonary embolism has yet been found. Streptokinase is widely used for the treatment of peripheral arterial disease on the Continent, but this approach has not been tested widely in Britain.
